title: The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor.
abstract: Aldosterone binds to the mineralocorticoid receptor (MR) and exerts fine control over Na+ absorption in renal collecting duct cells (CCDs). Many natural and synthetic steroids can also bind to the MR to produce agonist or antagonist effects. Here, we investigate whether androgenic hormones act as MR agonist or antagonist ligands in CCDs. Testosterone (T), dihydrotestosterone (DHT), and methyltrienolone (R1881), a synthetic androgen agonist, all bind to the MR. R1881 displayed the same affinity for MR as aldosterone. Androgens did not activate the MR transiently expressed in human embryonic kidney 293T cells but did antagonize aldosterone-induced MR trans-activation activity (R1881>DHT>T). Short-circuit current (Isc) experiments, used to measure transepithelial Na+ transport, revealed that 10(-5) M T and DHT or R1881 prevented the increase in the amiloride-sensitive component of Isc caused by aldosterone in mouse mpkCCDcl4 collecting duct cells partially and totally, respectively. In contrast, androgens had no effect on stimulated Isc elicited by the specific glucocorticoid agonist 11beta,17beta-dihydroxy-17alpha-(1-propynyl) and rost-1,4,6-trien-3-one (RU26988). Docking of steroids within the crystal structure of the ligand-binding domain of MR, together with trans-activation studies, revealed that the contacts between the 17beta-hydroxyl group of androgens and the Asn770, Cys942, and Thr945 residues of the ligand-binding cavity stabilize ligand binding complexes but are not strong enough to keep the receptor in its active state. Altogether, these findings indicate that androgen ligands, particularly R1881, act as MR antagonists in aldosterone target cells and provide new insights into the requirements for MR activation to occur and for the designing of new selective MR antagonists.
authors.affiliation: INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon (CRB3), BP 416, 16 rue Henri Huchard, F-75870, Paris, France.
authors.forename: Armelle-Natsuo
authors.initials: AN
authors.lastname: Takeda
authors.forename: Grégory M
authors.initials: GM
authors.lastname: Pinon
authors.forename: Marcelle
authors.initials: M
authors.lastname: Bens
authors.forename: Jérôme
authors.initials: J
authors.lastname: Fagart
authors.forename: Marie-Edith
authors.initials: ME
authors.lastname: Rafestin-Oblin
authors.forename: Alain
authors.initials: A
authors.lastname: Vandewalle
mesh_terms: D000728:Androgens / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002460:Cell Line; D004594:Electrophysiology; D006801:Humans; D007668:Kidney / Q000166:cytology; D008024:Ligands; D015741:Metribolone / Q000494:pharmacology*; D051379:Mice; D000451:Mineralocorticoid Receptor Antagonists; D012964:Sodium / Q000378:metabolism; D045165:Testosterone Congeners / Q000494:pharmacology
chemical_list: D000728:Androgens; D008024:Ligands; D000451:Mineralocorticoid Receptor Antagonists; D045165:Testosterone Congeners; D015741:Metribolone; D012964:Sodium